According to this month's Muscular Development magazine, an Australian pharmaceutical company called Acrux has just just finished a phase II clinical trial in the United States for a quick drying testosterone spray.
The spray contains "penetration enhancing agents" that aid in delivering a greater amount of drug to the skin and would allow it to dry much quicker than current TRT gels.
This product was designed to be applied daily to the - get this - underarms, so as to minimize person-to-person transference. In fact, the company is considering adding an antiperspirant and/or deodorant to the product.
The trial followed 41 hypogonadal men who received either a 30 or 60 mg daily dose. The lower dose restored normal T concentrations in 76% of men, 88% for the higher dose, with an average serum concentration of 510 ng/dL.
There were no adverse effects noted except for three reports of mild skin irritation and one peak T reading of 1500 ng/dL.
The product is currently known as Testosterone MD Lotion.
The spray contains "penetration enhancing agents" that aid in delivering a greater amount of drug to the skin and would allow it to dry much quicker than current TRT gels.
This product was designed to be applied daily to the - get this - underarms, so as to minimize person-to-person transference. In fact, the company is considering adding an antiperspirant and/or deodorant to the product.
The trial followed 41 hypogonadal men who received either a 30 or 60 mg daily dose. The lower dose restored normal T concentrations in 76% of men, 88% for the higher dose, with an average serum concentration of 510 ng/dL.
There were no adverse effects noted except for three reports of mild skin irritation and one peak T reading of 1500 ng/dL.
The product is currently known as Testosterone MD Lotion.